Skip to main content
VivoSim Labs, INC. logo

VivoSim Labs, INC. — Investor Relations & Filings

Ticker · VIVS ISIN · US68620A2033 US Professional, scientific and technical activities
Open in API
Filings indexed 790 across all filing types
Latest filing 2018-08-17 Director's Dealing
Country US United States of America
Listing US VIVS

About VivoSim Labs, INC.

https://organovo.com/

VivoSim Labs, Inc. is a biotechnology services company that develops and utilizes bioprinted, three-dimensional (3D) human tissues designed to emulate human biology and disease. The company provides testing services for drugs and drug candidates, primarily for the pharmaceutical and biotechnology sectors. VivoSim Labs specializes in offering liver and intestinal toxicology insights through its proprietary New Approach Methodologies (NAMs), including its NAMkind™ 3D models. These non-animal testing platforms are used to generate human-relevant safety and toxicology data early in the drug discovery and development process, aiming to provide insights before animal studies or clinical trials.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2018-08-17 English
FORM 4 SUBMISSION
Director's Dealing
2018-08-17 English
FORM 4 SUBMISSION
Director's Dealing
2018-08-17 English
FORM 4 SUBMISSION
Director's Dealing
2018-08-16 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 15, 2018, by Organovo Holdings, Inc. The content focuses on the granting of stock option awards to named executive officers by the Compensation Committee. It details the rationale behind the awards, the number of options granted to each executive, vesting schedules, and exercise prices. This is a clear announcement of changes related to executive compensation and appointments, specifically stock option grants to senior management. There is no financial statement or comprehensive report data, so it is not an Annual Report, Interim Report, or Earnings Release. The document fits the category of Board/Management Information (MANG), which includes announcements of changes in senior management or board-related compensation decisions. The document length (6280 characters) and detailed content support this classification with high confidence.
2018-08-15 English
S-8
Capital/Financing Update Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC by Organovo Holdings, Inc. It registers shares of common stock under an equity incentive plan. The text includes details about the registration fee, incorporation by reference of other filings (such as 10-K, 10-Q, 8-K), and legal indemnification provisions. Form S-8 is a registration statement used to register securities to be offered to employees under stock plans. It is not a financial report, earnings release, or management discussion. It is a capital markets filing related to securities registration and equity incentive plans. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including securities registration statements.
2018-08-14 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.